HomeNewsBusinessMarketsStimulus package 2.0 to benefit Rs 30,000 cr PVC pipes segment; Finolex, Astral Poly top buys

Stimulus package 2.0 to benefit Rs 30,000 cr PVC pipes segment; Finolex, Astral Poly top buys

The domestic brokerage house initiates a buy rating on Finolex Industries with a 2-year target price of Rs 492 while Astral Poly is also a buy with a 2-year target price of Rs 1081.

May 21, 2020 / 08:25 IST
Story continues below Advertisement
Maharashtra Seamless
Maharashtra Seamless

The Indian plastic pipe industry is likely to clock 10 percent CAGR over FY20-25E to reach Rs 50,000 billion by FY25E from Rs30,000 crore currently, driven by government’s initiatives like “Housing for All” by 2022, “Nal se Jal” by 2024, project AMRUT & Swachh Bharat Mission, Reliance Securities said in a note.

Story continues below Advertisement

The stimulus package for Agri and Housing sector announced by the Finance Minister recently is likely to benefit the PVC Pipes segment. The government has announced stimulus packages in V tranches to fight against disruption of COVID19.

“We believe package III is likely to benefit Farmers and Housing sector,” said the note. Reliance Securities initiates coverage with a buy rating on Finolex Industries, and Astral Poly with a 2-year investment horizon.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show
 The company is the largest player in agriculture pipes and 2nd largest player in the Indian pipes sector with a market share of 9 percent.

Finolex has increased its PVC pipes capacity to 370,000 TPA currently from 250,000 TPA in FY15, while resin capacity remains at 272,000 TPA.

It has forayed into the CPVC segment with a tie-up with Lubrizol in February 2017. Reliance Securities initiated coverage on Finolex with a buy recommendation and 2-Year Target Price of Rs492 (valuing it at 16x FY23E earnings).

Astral Poly Technik (Astral):
The company is the leader in CPVC pipes and fittings market in India. Astral had innovated CPVC pipes in India 2 decades ago and gained significant traction by introducing the various applications.With the expansion in Odisha, its total capacity will increase to 250,000 MTPA by FY21E. Astral has entered the adhesives business through the acquisition of Seal IT and Resinova, which has helped to gain a strong base.Reliance Securities initiated coverage on Astral with a BUY recommendation and 2-Year Target Price of Rs1,081 (45x FY23E earnings).

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.